<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yu X</submitter><funding>Strategic Collaborative Innovation Team</funding><funding>National Natural Science Funds of China</funding><funding>Shanghai Three-year Action Plan for Public Health under Grant</funding><pagination>10980</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8535751</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(20)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Ensuring adherence guarantees the efficacy of pre-exposure prophylaxis (PrEP).&lt;h4>Methods&lt;/h4>We conducted a cross-sectional study among 816 sexually transmitted infection (STI) patients in Shanghai. The questionnaire included self-reported demographic characteristics, self-administered items on adherence to free oral PrEP, and PrEP uptake behavior measurement. We conducted item analysis, reliability analysis, validity analysis and receiver operating characteristic (ROC) curve analysis.&lt;h4>Results&lt;/h4>Not all items were considered acceptable in the item analysis. The questionnaire had a McDonald's ω coefficient of 0.847. The scale-level content validity index (CVI) was 0.938 and the item-level CVI of each item ranged from 0.750 to 1. In exploratory factor analysis, we introduced a four-factor model accounting for 79.838% of the aggregate variance, which was validated in confirmatory factor analysis. Adding PrEP adherence questionnaire scores contributed to prediction of PrEP uptake behavior (&lt;i>p&lt;/i> &lt; 0.001) in regression analysis. The maximum area under the ROC curve was 0.778 (95% IC: 0.739-0.817).&lt;h4>Conclusion&lt;/h4>The PrEP adherence questionnaire presented psychometric validation among STI patients.</pubmed_abstract><journal>International journal of environmental research and public health</journal><pubmed_title>Pre-Exposure Prophylaxis (PrEP) Adherence Questionnaire: Psychometric Validation among Sexually Transmitted Infection Patients in China.</pubmed_title><pmcid>PMC8535751</pmcid><funding_grant_id>SSMU-ZLCX20180601)</funding_grant_id><funding_grant_id>71603166, 71673187</funding_grant_id><funding_grant_id>GWV-10.2-XD13, GWV-10.1-XK15, GWV-10.1-XK18</funding_grant_id><pubmed_authors>Ni Y</pubmed_authors><pubmed_authors>Chang R</pubmed_authors><pubmed_authors>Gong R</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Cai Y</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Yu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pre-Exposure Prophylaxis (PrEP) Adherence Questionnaire: Psychometric Validation among Sexually Transmitted Infection Patients in China.</name><description>&lt;h4>Background&lt;/h4>Ensuring adherence guarantees the efficacy of pre-exposure prophylaxis (PrEP).&lt;h4>Methods&lt;/h4>We conducted a cross-sectional study among 816 sexually transmitted infection (STI) patients in Shanghai. The questionnaire included self-reported demographic characteristics, self-administered items on adherence to free oral PrEP, and PrEP uptake behavior measurement. We conducted item analysis, reliability analysis, validity analysis and receiver operating characteristic (ROC) curve analysis.&lt;h4>Results&lt;/h4>Not all items were considered acceptable in the item analysis. The questionnaire had a McDonald's ω coefficient of 0.847. The scale-level content validity index (CVI) was 0.938 and the item-level CVI of each item ranged from 0.750 to 1. In exploratory factor analysis, we introduced a four-factor model accounting for 79.838% of the aggregate variance, which was validated in confirmatory factor analysis. Adding PrEP adherence questionnaire scores contributed to prediction of PrEP uptake behavior (&lt;i>p&lt;/i> &lt; 0.001) in regression analysis. The maximum area under the ROC curve was 0.778 (95% IC: 0.739-0.817).&lt;h4>Conclusion&lt;/h4>The PrEP adherence questionnaire presented psychometric validation among STI patients.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2026-07-09T11:58:19.222Z</modification><creation>2025-04-07T02:26:10.424Z</creation></dates><accession>S-EPMC8535751</accession><cross_references><pubmed>34682730</pubmed><doi>10.3390/ijerph182010980</doi></cross_references></HashMap>